SAB Biotherapeutics (SABS) Revenue & Revenue Breakdown
SAB Biotherapeutics Revenue Highlights
Latest Revenue (Y)
$2.24M
Latest Revenue (Q)
$263.14K
Main Segment (Y)
Grant Revenue
Main Geography (Y)
Grant Revenue
SAB Biotherapeutics Revenue by Period
SAB Biotherapeutics Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $2.24M | -90.63% |
2022-12-31 | $23.90M | -60.73% |
2021-12-31 | $60.88M | 10.21% |
2020-12-31 | $55.24M | 1504.91% |
2019-12-31 | $3.44M | - |
SAB Biotherapeutics Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-06-30 | $263.14K | -72.14% |
2024-03-31 | $944.58K | 209.69% |
2023-12-31 | $305.01K | -75.93% |
2023-09-30 | $1.27M | 1381.98% |
2023-06-30 | $85.52K | -85.28% |
2023-03-31 | $581.10K | -73.11% |
2022-12-31 | $2.16M | -39.80% |
2022-09-30 | $3.59M | -43.47% |
2022-06-30 | $6.35M | -46.20% |
2022-03-31 | $11.80M | -80.61% |
2021-12-31 | $60.88M | 100.00% |
2021-09-30 | - | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | 100.00% |
2020-12-31 | - | - |
SAB Biotherapeutics Revenue Breakdown
SAB Biotherapeutics Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 21 |
---|---|
Grant Revenue | $60.88M |
Quarterly Revenue by Product
Product/Service | Sep 22 | Jun 22 | Mar 22 |
---|---|---|---|
Grant Revenue | $3.59M | $6.35M | $11.80M |
SAB Biotherapeutics Revenue Breakdown by Country
Annual Revenue by Country
Country | Dec 21 |
---|---|
Grant Revenue | $60.88M |
Quarterly Revenue by Country
Country | Sep 22 | Jun 22 | Mar 22 |
---|---|---|---|
Grant Revenue | $3.59M | $6.35M | $11.80M |
SAB Biotherapeutics Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
FRTX | Fresh Tracks Therapeutics | $8.01M | - |
SABS | SAB Biotherapeutics | $2.24M | $263.14K |
UNCY | Unicycive Therapeutics | $675.00K | - |
VRAX | Virax Biolabs Group | $8.56K | $76.50K |
ANEB | Anebulo Pharmaceuticals | - | - |
PXMD | PaxMedica | - | - |
PCSA | Processa Pharmaceuticals | - | - |
CVKD | Cadrenal Therapeutics | - | - |
MNPR | Monopar Therapeutics | - | - |
THRD | Third Harmonic Bio | - | - |
QNRX | Quoin Pharmaceuticals | - | - |
CDIO | Cardio Diagnostics | - | $7.87K |
SABS Revenue FAQ
What is SAB Biotherapeutics’s yearly revenue?
SAB Biotherapeutics's yearly revenue for 2023 was $2.24M, representing a decrease of -90.63% compared to 2022. The company's yearly revenue for 2022 was $23.9M, representing a decrease of -60.73% compared to 2021. SABS's yearly revenue for 2021 was $60.88M, representing an increase of 10.21% compared to 2020.
What is SAB Biotherapeutics’s quarterly revenue?
SAB Biotherapeutics's quarterly revenue for Q2 2024 was $263.14K, a -72.14% decrease from the previous quarter (Q1 2024), and a 207.70% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $944.58K, a 209.69% increase from the previous quarter (Q4 2023), and a 62.55% increase year-over-year (Q1 2023). SABS's quarterly revenue for Q4 2023 was $305.01K, a -75.93% decrease from the previous quarter (Q3 2023), and a -85.88% decrease year-over-year (Q4 2022).
What is SAB Biotherapeutics’s revenue growth rate?
SAB Biotherapeutics's revenue growth rate for the last 3 years (2021-2023) was -96.32%, and for the last 5 years (2019-2023) was -34.95%.
What are SAB Biotherapeutics’s revenue streams?
SAB Biotherapeutics's revenue streams in c 21 are Grant Revenue
What is SAB Biotherapeutics’s main source of revenue?
For the fiscal year ending Dec 21, the largest source of revenue of SAB Biotherapeutics was Grant Revenue. This segment made a revenue of $60.88M, representing 100.00% of the company's total revenue.